Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Apr;38(4):713–718. doi: 10.1128/aac.38.4.713

Pharmacokinetics and safety of a unilamellar liposomal formulation of amphotericin B (AmBisome) in rabbits.

J W Lee 1, M A Amantea 1, P A Francis 1, E E Navarro 1, J Bacher 1, P A Pizzo 1, T J Walsh 1
PMCID: PMC284530  PMID: 8031034

Abstract

A unilamellar liposomal formulation of amphotericin B (LAmB) known as AmBisome was safely administered intravenously to 20 rabbits at 0.5, 1.0, 2.5, 5, or 10 mg/kg of body weight, whereas of 12 rabbits given desoxycholate amphotericin B (DAmB) intravenously at 0.5, 1.0, or 1.5 mg/kg, 2 died of acute cardiac toxicity when DAmB was administered at the highest dose. Single-dose LAmB (1 mg/kg) achieved a maximum concentration in serum (Cmax) of 26 +/- 2.4 micrograms/ml and an area under the curve to infinity (AUC0-infinity) of 60 +/- 16 micrograms.h/ml, while single-dose DAmB (1.0 mg/kg), by comparison, achieved a lower Cmax (4.7 +/- 0.2 micrograms/ml; P = 0.001) and a lower AUC0-infinity (30.6 +/- 2.2 micrograms.h/ml; P = 0.07). Following administration of a single dose of LAmB (10 mg/kg), a disproportionately higher Cmax (287 +/- 14 micrograms/ml) and AUC0-infinity (2,223 +/- 246 micrograms.h/ml) occurred, indicating saturable elimination. After chronic dosing (n = 4) with LAmB at 5.0 mg/kg/day for 28 days or DAmB at 1.0 mg/kg/day for 28 days, LAmB achieved daily peak levels of 122.8 +/- 5.8 micrograms/ml and trough levels of 34.9 +/- 1.8 micrograms/ml, while DAmB reached a peak of only 1.76 +/- 0.11 microgram/ml and a trough of 0.46 +/- 0.04 microgram/ml (P < or = 0.001). Significant accumulations of amphotericin B into reticuloendothelial organs were observed, with 239 +/- 39 micrograms/g found in the liver after chronic LAmB dosing (5 mg/kg/day), which was seven times higher than the 33 +/- 6 micrograms/g after DAmB dosing (1 mg/kg/day) (P = 0.002). Accumulation in kidneys, however, remained 14-fold lower (P =0.04) following LAmB dosing (0.87 +/- 0.61 microgram/g) than after DAmB dosing (12.7 +/- 4.6 microgram/g). Nephrotoxicity occurred in only one of four LAmB treated animals, while it occurred in all four chronically DAmB-treated animals: mild hepatozicity with transaminase elevations was seen in one LAmB-treated rabbit. We conclude that LAmB safely achieved higher Cmax(s) and AUC0-infinity(s) and demonstrated saturable, nonlinear elimination from plasma via reticuloendothelial organ uptake. Take reduced nephrotoxicity of LAmB correlated with diminished levels of amphotericin B in the kidneys.

Full text

PDF
713

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abra R. M., Hunt C. A. Liposome disposition in vivo. III. Dose and vesicle-size effects. Biochim Biophys Acta. 1981 Dec 23;666(3):493–503. doi: 10.1016/0005-2760(81)90311-8. [DOI] [PubMed] [Google Scholar]
  2. Brassinne C., Laduron C., Coune A., Sculier J. P., Hollaert C., Collette N., Meunier F. High-performance liquid chromatographic determination of amphotericin B in human serum. J Chromatogr. 1987 Aug 7;419:401–407. doi: 10.1016/0378-4347(87)80307-9. [DOI] [PubMed] [Google Scholar]
  3. Chopra R., Blair S., Strang J., Cervi P., Patterson K. G., Goldstone A. H. Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):93–104. doi: 10.1093/jac/28.suppl_b.93. [DOI] [PubMed] [Google Scholar]
  4. Coker R. J., Murphy S. M., Harris J. R. Experience with liposomal amphotericin B (AmBisome) in cryptococcal meningitis in AIDS. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):105–109. doi: 10.1093/jac/28.suppl_b.105. [DOI] [PubMed] [Google Scholar]
  5. Gregoriadis G. Overview of liposomes. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):39–48. doi: 10.1093/jac/28.suppl_b.39. [DOI] [PubMed] [Google Scholar]
  6. Lopez-Berestein G., Kasi L., Rosenblum M. G., Haynie T., Jahns M., Glenn H., Mehta R., Mavligit G. M., Hersh E. M. Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res. 1984 Jan;44(1):375–378. [PubMed] [Google Scholar]
  7. Meunier F., Prentice H. G., Ringdén O. Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):83–91. doi: 10.1093/jac/28.suppl_b.83. [DOI] [PubMed] [Google Scholar]
  8. Miller M. A. Reversible hepatotoxicity related to amphotericin B. Can Med Assoc J. 1984 Nov 15;131(10):1245–1247. [PMC free article] [PubMed] [Google Scholar]
  9. Proffitt R. T., Satorius A., Chiang S. M., Sullivan L., Adler-Moore J. P. Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):49–61. doi: 10.1093/jac/28.suppl_b.49. [DOI] [PubMed] [Google Scholar]
  10. Proffitt R. T., Williams L. E., Presant C. A., Tin G. W., Uliana J. A., Gamble R. C., Baldeschwieler J. D. Liposomal blockade of the reticuloendothelial system: improved tumor imaging with small unilamellar vesicles. Science. 1983 Apr 29;220(4596):502–505. doi: 10.1126/science.6836294. [DOI] [PubMed] [Google Scholar]
  11. Ringdén O., Meunier F., Tollemar J., Ricci P., Tura S., Kuse E., Viviani M. A., Gorin N. C., Klastersky J., Fenaux P. Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991 Oct;28 (Suppl B):73–82. doi: 10.1093/jac/28.suppl_b.73. [DOI] [PubMed] [Google Scholar]
  12. Walsh T. J., Bacher J., Pizzo P. A. Chronic silastic central venous catheterization for induction, maintenance and support of persistent granulocytopenia in rabbits. Lab Anim Sci. 1988 Aug;38(4):467–471. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES